REPL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Replimune Group Inc (REPL) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock faces significant regulatory challenges and lacks clear positive catalysts to justify immediate investment. While technical indicators show short-term bullish momentum, the broader outlook remains uncertain due to negative analyst sentiment and regulatory hurdles.
The stock shows bullish momentum with MACD positively expanding and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). RSI is in the neutral zone at 75.768, and the stock is trading near its resistance level of 10.133. However, historical trends suggest a high probability of negative returns over the next month (-8.76%).
The FDA has agreed on a path for resubmission of RP1 plus nivolumab in advanced melanoma, which could potentially lead to approval. JPMorgan views this as a 'clear win' for the company.
The company has faced multiple regulatory setbacks, including two complete response letters from the FDA for its RP1 therapy. Analysts have downgraded the stock significantly, citing a lack of alignment with the FDA and challenges in clinical data. The stock has a volatile regulatory history, and sentiment remains cautious.
No financial data is available for analysis.
Mixed to negative sentiment from analysts. Recent upgrades from JPMorgan and Wedbush raised price targets to $8 and $6, respectively, but the stock has been downgraded multiple times in the past due to regulatory challenges. The average price target remains below the current trading price, reflecting limited upside potential.
